Neurocrine Biosciences
$143.18Change from previous close: +1.76%Absolute change: +$2.47
At a glance
- Revenue growth
- +21.45%
- 2025 vs 2024
- Net income growth
- +40.23%
- 2025 vs 2024
- Net margin
- 16.7%
- 2024: 14.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 4,632 | 3,719 | 3,251 | 2,369 | — |
| Current assets | 2,523 | 1,725 | 1,607 | 1,454 | — |
| Cash and equivalents | 713 | 233 | 251 | 263 | — |
| Short-term investments | 767 | 843 | 781 | 726 | — |
| Receivables | 687 | 479 | 439 | 350 | — |
| Inventory | 69.0 | 57.4 | 38.3 | 35.1 | — |
| Net property, plant and equipment | 545 | 592 | 347 | 146 | — |
| Other intangible assets | — | 36.5 | 35.5 | 37.2 | — |
| Long-term investments | 1,184 | 864 | 849 | 402 | — |
| Current liabilities | 743 | 508 | 655 | 538 | — |
| Accounts payable | 105 | 99.9 | 133 | 67.3 | — |
| Long-term debt | — | — | — | — | 335 |
| Total debt | 415 | 455 | 428 | 263 | — |
| Total liabilities | 1,378 | 1,129 | 1,019 | 661 | — |
| Total equity (incl. minority) | 3,253 | 2,590 | 2,232 | 1,708 | — |
| Retained earnings | 448 | 29.2 | -157 | -407 | — |